JD Vance Predicts: Wall Street vs. Trump & Your Money

Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.

Get your free guide NOW before it's too late.

Ryan Spencer Biography and Net Worth

CEO of Dynavax Technologies

Mr. Spencer, joined Dynavax in 2005 and currently serves as Chief Executive Officer. Previously, Mr. Spencer served as Senior Vice President of Commercial where he was instrumental in leading the launch and commercialization of HEPLISAV-B. Throughout his time at Dynavax, Mr. Spencer has held a variety of positions with increasing responsibility, building from a foundation in corporate finance to business strategy and investor relations. Prior to joining Dynavax, Mr. Spencer was the Assistant Controller at QRS Corporation, a publicly-held technology company, and was a member of the audit practice at Ernst & Young. Mr. Spencer earned a B.A. in Business Economics from University of California, Santa Barbara.

What is Ryan Spencer's net worth?: The estimated net worth of Ryan Spencer is at least $1.76 million as of August 9th, 2022. Mr. Spencer owns 144,513 shares of Dynavax Technologies stock worth more than $1,758,723 as of November 20th. This net worth estimate does not reflect any other investments that Mr. Spencer may own. Additionally, Mr. Spencer receives a salary of $1,490,000.00 as CEO at Dynavax Technologies. Learn More about Ryan Spencer's net worth.
How old is Ryan Spencer?: Mr. Spencer is currently 46 years old. There are 5 older executives and no younger executives at Dynavax Technologies. Learn More on Ryan Spencer's age.
What is Ryan Spencer's salary?: As the CEO of Dynavax Technologies Co., Mr. Spencer earns $1,490,000.00 per year. Learn More on Ryan Spencer's salary.
How do I contact Ryan Spencer?: The corporate mailing address for Mr. Spencer and other Dynavax Technologies executives is 2100 Powell Street Suite 900, Emeryville CA, 94608. Dynavax Technologies can also be reached via phone at (510) 848-5100 and via email at [email protected]. Learn More on Ryan Spencer's contact information.
Has Ryan Spencer been buying or selling shares of Dynavax Technologies?: Ryan Spencer has not been actively trading shares of Dynavax Technologies within the last three months. Most recently, Ryan Spencer sold 14,921 shares of the business's stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $16.92, for a transaction totalling $252,463.32. Following the completion of the sale, the chief executive officer now directly owns 144,513 shares of the company's stock, valued at $2,445,159.96. Learn More on Ryan Spencer's trading history.
Who are Dynavax Technologies' active insiders?: Dynavax Technologies' insider roster includes Justin Burgess (Insider), Andrew Hack (Director), Robert Janssen (SVP), Kelly MacDonald (Sr. VP & CFO ), David Novack (COO), and Ryan Spencer (CEO). Learn More on Dynavax Technologies' active insiders.
Are insiders buying or selling shares of Dynavax Technologies?: In the last year, insiders at the biopharmaceutical company sold shares 5 times. They sold a total of 54,641 shares worth more than $729,199.23. The most recent insider tranaction occured on May, 31st when Director Francis Cano sold 3,615 shares worth more than $43,126.95. Insiders at Dynavax Technologies own 3.0% of the company. Learn More about insider trades at Dynavax Technologies.
Information on this page was last updated on 5/31/2024.

Ryan Spencer Insider Trading History at Dynavax Technologies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/9/2022	Sell	14,921	$16.92	$252,463.32	144,513
3/3/2022	Sell	83,108	$10.56	$877,620.48

Ryan Spencer Buying and Selling Activity at Dynavax Technologies

Dynavax Technologies Company Overview

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Today's Range

Now: $12.17

$11.75

$12.24

50 Day Range

MA: $11.45

$10.28

$13.66

2 Week Range

Now: $12.17

$9.74

$15.01

Volume

1,352,748 shs

Average Volume

3,092,731 shs

Market Capitalization

$1.60 billion

P/E Ratio

93.62

Dividend Yield

N/A

Beta

1.34

JD Vance Predicts: Wall Street vs. Trump & Your Money

From Priority Gold | Ad

Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.

Get your free guide NOW before it's too late.

Ryan Spencer Biography and Net Worth

What is Ryan Spencer's net worth?

How old is Ryan Spencer?

What is Ryan Spencer's salary?

How do I contact Ryan Spencer?

Has Ryan Spencer been buying or selling shares of Dynavax Technologies?

Who are Dynavax Technologies' active insiders?

Are insiders buying or selling shares of Dynavax Technologies?